Anti-CD38 monoclonal antibody that kills malignant plasma cells via ADCC, CDC, ADCP, and direct apoptosis.
Anti-CD38 IgG1κ monoclonal antibody that binds CD38 on malignant plasma cells, inducing Fc-mediated ADCC, CDC, and ADCP and direct apoptosis; also depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs), contributing to antitumor immunity.
Anti-CD38 mAb binds CD38 on target cells and triggers Fc-mediated ADCC, CDC, and ADCP, and can induce direct apoptosis of CD38+ cells.
First-generation small-molecule BCR-ABL1 tyrosine kinase inhibitor (also inhibits KIT and PDGFR) that blocks leukemic cell proliferation and survival.
ATP-competitive tyrosine kinase inhibitor that targets BCR-ABL1 and also inhibits KIT and PDGFR, blocking oncogenic signaling to suppress proliferation and induce apoptosis of leukemic cells (e.g., Ph+ ALL/CML).
Imatinib directly inhibits the BCR-ABL1 tyrosine kinase (ATP-competitive), shutting down survival/proliferation signaling and triggering cell cycle arrest and apoptosis in BCR-ABL1–expressing leukemic cells.
First-generation small-molecule BCR-ABL1 tyrosine kinase inhibitor (also inhibits KIT and PDGFR) that blocks leukemic cell proliferation and survival.
ATP-competitive tyrosine kinase inhibitor that targets BCR-ABL1 and also inhibits KIT and PDGFR, blocking oncogenic signaling to suppress proliferation and induce apoptosis of leukemic cells (e.g., Ph+ ALL/CML).
Imatinib directly inhibits KIT tyrosine kinase activity (ATP-competitive), blocking downstream survival/proliferation signaling (e.g., PI3K/AKT, RAS/MAPK), leading to growth arrest and apoptosis of KIT-dependent tumor cells.
First-generation small-molecule BCR-ABL1 tyrosine kinase inhibitor (also inhibits KIT and PDGFR) that blocks leukemic cell proliferation and survival.
ATP-competitive tyrosine kinase inhibitor that targets BCR-ABL1 and also inhibits KIT and PDGFR, blocking oncogenic signaling to suppress proliferation and induce apoptosis of leukemic cells (e.g., Ph+ ALL/CML).
ATP-competitive inhibition of PDGFRA kinase blocks downstream survival/proliferation signaling (e.g., MAPK/PI3K), causing growth arrest and apoptosis of PDGFRA-dependent cells.
First-generation small-molecule BCR-ABL1 tyrosine kinase inhibitor (also inhibits KIT and PDGFR) that blocks leukemic cell proliferation and survival.
ATP-competitive tyrosine kinase inhibitor that targets BCR-ABL1 and also inhibits KIT and PDGFR, blocking oncogenic signaling to suppress proliferation and induce apoptosis of leukemic cells (e.g., Ph+ ALL/CML).
Imatinib directly inhibits PDGFRB tyrosine kinase activity, blocking survival/proliferation signaling and inducing growth arrest and apoptosis in PDGFRB-driven cells.